Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01521845
Other study ID # 90-1-94-8048
Secondary ID
Status Completed
Phase Phase 3
First received January 19, 2012
Last updated December 6, 2012
Start date January 2012
Est. completion date May 2012

Study information

Verified date December 2012
Source hahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of omega 3 on biomarkers of cardiac necrosis(CKMB and troponin I) and inflammation marker CRP.


Description:

Percutaneous coronary intervention (PCI) has become the most common form of coronary revascularization worldwide. Although PCI is a safe procedure, it may have multiple risks including bleeding, coronary dissection, abrupt vessel closure, and myocardial necrosis. It is estimated that approximately 25% of patients undergoing PCI have significant postprocedural creatinine kinase (CK)/creatinine kinase myocardial band (CK-MB) elevations and approximately 50% of patients have significant post-procedural troponin elevations. Initially, it was felt these elevations were simple enzyme leaks with no long-term implications.

Now, several studies have demonstrated that periprocedural infarction is associated with short-, intermediate-, and long-term adverse outcomes, most notably mortality. Pretreatment with antiplatelets such as aspirin and clopidogrel play an important role in reducing cardiovascular events (CV events) following PCI.

Omega -3 polyunsaturated fatty acids (PUFAs) have antiplatelet effect. It may also improve response to aspirin and clopidogrel in low-response patients.

This study is a randomized clinical trial (RCT) evaluating the effect of omega 3 supplement [with 400mg Eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA)] on biomarkers of cardiac necrosis (CKMB and troponin I) in patients undergoing elective PCI. Eighty patients planed to do elective PCI will be categorized into two groups. The first group will be received standard regimen for PCI (aspirin, clopidogrel, and heparin) and the second group will be treated with standard regimen in addition to 3 gram omega 3 (12 hours before PCI). Blood samples will be drawn in all patients before and 8 and 24 h after intervention for cardiac biomarkers assessment (CK-MB, troponin I)and inflammation marker C-reactive protein (CRP). Major adverse cardiac events (MACE) will be evaluated as a second endpoint.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date May 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- candidate of elective PCI

- treatment with aspirin at least 5 days before PCI

Exclusion Criteria:

- high CKMB and troponin I level

- cardiac bypass in recent 3 months

- platelet count < 70×10 9/L

- sever chronic renal failure

- active bleeding

- treatment with glycoprotein IIb/IIIa inhibitors during PCI

- treatment with bivalirudin during PCI

- sensitivity to aspirin and clopidogrel

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention


Intervention

Drug:
omega 3
3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI

Locations

Country Name City State
Iran, Islamic Republic of Moddaress Hospital Tehran

Sponsors (1)

Lead Sponsor Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiac Necrosis Biomarkers (CKMB, Troponin I) difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention 8 and 24 hrs after percutaneous coronary intervention No
Primary Inflammation Marker (CRP) difference between study and control group in 8 and 24 hrs after percutaneous coronary intervention 8 and 24 hrs after percutaneous coronary intervention No
Secondary MACE(Major Adverse Cardiac Effect) Defined as Need for Target Revascularization, Myocardial Infarction and Death 30 days No
See also
  Status Clinical Trial Phase
Completed NCT00069654 - Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease Phase 2
Completed NCT02919124 - Epicardial Echocardiography of Coronary Anastomoses Using the Echoclip Device N/A
Recruiting NCT02639962 - Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study N/A
Completed NCT02494557 - Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients N/A
Recruiting NCT01466452 - Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery Phase 2
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00368953 - YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus Phase 4
Completed NCT00371891 - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Phase 4
Completed NCT00319449 - Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED) Phase 4
Completed NCT00091754 - Atherosclerosis, Plaque and CVD in Communities
Completed NCT00069797 - Epidemiology of Coronary Heart Disease in Men Aged 40 and Over N/A
Completed NCT00037245 - Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA N/A
Completed NCT00024596 - Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) N/A
Withdrawn NCT00006497 - Long-Term Effects of Subclinical CAD on Cardiac Function
Completed NCT00006502 - Myocardial Perfusion, Risk Factors, and Coronary Calcium N/A
Completed NCT00006407 - Sex Steroid Hormones and Risk of CHD in Women N/A
Completed NCT00006309 - Pooling of Cohort Studies on Diet & Coronary Disease N/A
Completed NCT00005269 - Family Blood Pressure Program - GENOA
Completed NCT00000508 - Stanford Coronary Risk Intervention Project (SCRIP) Phase 3
Completed NCT00005147 - Epidemiology of Atherosclerosis N/A